What does cannabis research say about dravet syndrome? We've analyzed 1 peer-reviewed studies to give you an honest, evidence-based overview.
Some clinical evidence supports potential benefits.
Study found evidence of effectiveness
* Outcomes are based on our curated selection of research reviews. Individual study quality varies.
About This Research Summary: The information below aggregates findings from multiple peer-reviewed studies on cannabis and dravet syndrome. This is for educational purposes only.
Research summaries are our interpretations of published studies. Individual responses to cannabis vary significantly. These findings do not guarantee similar results for any individual.
Study data sourced from PubMed®. Not evaluated by the FDA. See our Research Content Policy.
Long-term CBD treatment had an acceptable safety profile and led to sustained, clinically meaningful reductions in seizure frequency in patients with treatment-resistant Dravet syndrome.
Our reviews are just a starting point. Browse thousands more studies on PubMed for dravet syndrome.
Dravet Syndrome is a qualifying condition in many states. Our licensed physicians can evaluate whether medical cannabis is right for you.
Research Summary Disclaimer
This content represents our interpretation of published scientific research for educational purposes. It should not be used to make treatment decisions without consulting a qualified healthcare provider. Individual results may vary from study findings.
FDA Notice
These statements have not been evaluated by the FDA. Cannabis is not intended to diagnose, treat, cure, or prevent any disease. The FDA has not approved cannabis for any medical condition except specific prescription medications.
Copyright & Fair Use
Research summaries are provided under fair use (17 U.S.C. § 107) for educational purposes. We provide brief summaries with attribution, not full reproductions. All studies remain the intellectual property of their respective authors and publishers.
For complete information, see our Terms of Use and Research Content Policy.
